Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2

Prostate

Volumn 73, Issue 6, 2013, Pages 582-589

  Gupta, Aparna ^a   Yu, Xiuping ^b   Case, Tom ^b   Paul, Manik ^b   Shen, Michael M ^c   Kaestner, Klaus H ^d   Matusik, Robert J ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Foxa2; Mash1; neuroendocrine; prostate; TRAMP

Indexed keywords

ANDROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3BETA; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR MASH1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREEDING; CONTROLLED STUDY; DISEASE MODEL; GENE FREQUENCY; KNOCKOUT MOUSE; LIMB BUD; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; SIMIAN VIRUS 40; UPREGULATION; WILD TYPE;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, SMALL CELL; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-BETA; MALE; MICE; MICE, TRANSGENIC; NEUROENDOCRINE TUMORS; PHENOTYPE; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875810051     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22598     Document Type: Article

References (29)

1. di Sant'Agnese PA,. Neuroendocrine differentiation in prostatic carcinoma: An update. Prostate Suppl 1998; 8: 74-79.
2. Abrahamsson PA,. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999; 6: 503-519.
3. Ito T, Yamamoto S, Ohno Y, Namiki K, Aizawa T, Akiyama A, Tachibana M,. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. Oncol Rep 2001; 8: 1221-1224.
4. Chuang CK, Wu TL, Tsao KC, Liao SK,. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer. J Formos Med Assoc 2003; 102: 480-485.
5. Tarle M, Ahel MZ, Kovacic K,. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Anticancer Res 2002; 22: 2525-2529.
6. Best CJ, Gillespie JW, Yi Y, Chandramouli GVR, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, Gonzalez S, Velasco A, Linehan WM, Matusik RJ, Price D, Figg WD, Emmert-Buck MR, Chuaqui RF,. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005; 11: 6823-6834.
7. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ,. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004; 64: 5489-5495.
8. Uchida K, Masumori N, Takahashi A, Itoh N, Kato K, Matusik RJ, Tsukamoto T,. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate 2006; 66: 536-545.
9. Jin RJ, Lho Y, Connelly L, Wang Y-Q, Yu X, Saint Jean L, Case T, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ,. The nuclear factor kappa B pathway controls progression of prostate cancer to androgen independent growth. Cancer Res 2008; 68: 6762-6769.
10. Gupta A, Wang Y-Q, Browne C, Kim S, Case TC, Paul M, Matusik RJ,. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells. Prostate 2008; 68: 50-60.
11. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ,. Expression and role of Foxa proteins in prostate cancer. Prostate 2006; 66: 1013-1029.
12. Hu Y, Ippolito JE, Garabedian EM, Humphrey PA, Gordon JI,. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 2002; 277: 44462-44474.
13. Khoor A, Stahlman MT, Johnson JM, Olson SJ, Whitsett JA,. Forkhead box A2 transcription factor is expressed in all types of neuroendocrine lung tumors. Hum Pathol 2004; 35: 560-564.
14. Gao N, Le Lay J, Qin W, Doliba N, Schug J, Fox AJ, Smirnova O, Matschinsky FM, Kaestner KH,. Foxa1 and Foxa2 maintain the metabolic and secretory features of the mature beta-cell. Mol Endocrinol 2010; 24: 1594-1604.
15. Lee CS, Sund NJ, Behr R, Herrera PL, Kaestner KH,. Foxa2 is required for the differentiation of pancreatic alpha-cells. Dev Biol 2005; 278: 484-495.
16. Borges M, Linnoila RI, van de Velde HJ, Chen H, Nelkin BD, Mabry M, Baylin SB, Ball DW,. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 1997; 386: 852-855.
17. Sund NJ, Ang SL, Sackett SD, Shen W, Daigle N, Magnuson MA, Kaestner KH,. Hepatocyte nuclear factor 3beta (Foxa2) is dispensable for maintaining the differentiated state of the adult hepatocyte. Mol Cell Biol 2000; 20: 5175-5183.
18. Mirosevich J, Gao N, Matusik RJ,. Expression of Foxa transcription factors in the developing and adult murine prostate. Prostate 2005; 62: 339-352.
19. Gao N, Zhang J-F, Rao MA, Case TC, Mirosevich J, Wang Y, Jin R, Gupta A, Rennie PS, Matusik RJ,. The role of hepatocyte nuclear factor-3{alpha} (Foxa1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol 2003; 17: 1484-1507.
20. Gao N, Ishii K, Mirosevich J, Kuwajima S, Oppenheimer SR, Roberts RL, Jiang M, Yu X, Shappell SB, Caprioli RM, Stoffel M, Hayward SW, Matusik RJ,. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 2005; 132: 3431-3443.
21. DeGraff DJ, Yu X, Sun Q, Mirosevich J, Jin RJ, Wang Y-Q, Gupta A, Nandana S, Case TC, Paul M, Huang H-Y, Shapiro E, Logan SK, Suzuki K, Orgebin-Crist MC, Matusik RJ,. The role of Foxa proteins in the regulation of the androgen receptor activity. In:, Tindall DJ, Mohler JL, editors. Androgen action in prostate cancer. New York: Springer Science and Business Media; 2009. pp. 587-615.
22. Li Z, Tuteja G, Schug J, Kaestner KH,. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 2012; 148: 72-83.
23. Bort R, Zaret K,. Paths to the pancreas. Nat Genet 2002; 32: 85-86.
24. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz M, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM, Matusik RJ,. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994; 8: 230-239.
25. Yu X, Wang Y-Q, Jiang M, Bierie BB, Hayward SW, Shen MM, Taketo MM, Wills M, Matusik RJ,. Activated beta-catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate 2009; 69: 249-262.
26. Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ,. Wnt/beta-Catenin activation promotes prostate tumor progression in a mouse model. Oncogene 2011; 30: 1868-1879.
27. Mehta V, Abler LL, Keil KP, Schmitz CT, Joshi PS, Vezina CM,. Atlas of Wnt and R-spondin gene expression in the developing male mouse lower urogenital tract. Dev Dyn 2011; 240: 2548-2560.
28. Wu X, Daniels G, Shapiro E, Xu K, Huang H, Li Y, Logan S, Greco MA, Peng Y, Monaco ME, Melamed J, Lepor H, Grishina I, Lee P,. LEF1 identifies androgen-independent epithelium in the developing prostate. Mol Endocrinol 2011; 25: 1018-1026.
29. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D, Ronai ZA,. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 2010; 18: 23-38.